Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, herbal hair tonic made from Usada Bali ingredients significantly increased hair growth in mice without causing skin irritation compared to a negative control.

This study observes that TYK2 inhibition with BMS-986202 may extend hair follicle growth phases and decrease inflammatory cell markers in alopecia areata, suggesting potential for clinical application.

This study found that hinokitiol in cationic vesicles promoted hair growth in mice, potentially due to its high substantivity on the skin.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

Tofacitinib might be used to treat hair loss.

This review analyzes the mechanism and evidence supporting the approved use of ritlecitinib, a JAK3/TEC kinase inhibitor, for treating severe alopecia areata in patients aged 12 and older, highlighting its role in the changing therapeutic landscape of this immune-mediated disease.

This study found that short-term treatment with ROCKi significantly increased keratinocyte stem cell proliferation without affecting their stemness, suggesting a potential safe approach for improving in vitro keratinocyte cultures for clinical applications.

This study identified a new type II cytokeratin, named K6hf, exclusively expressed in the companion layer of the human hair follicle, distinguishing it from other keratins and suggesting a unique biochemical role.

This study discusses the development of AI in dermatology and cosmetology, noting its use in skin cancer diagnosis and personalized cosmetics, while highlighting uncertainties about whether recent advancements represent significant medical progress or are influenced by marketing strategies.

This study suggests that a prototype device may accurately measure hair quantity, diameter, and density in balding patients, potentially aiding in diagnostic assessments, though formal clinical studies are needed to confirm its effectiveness.

This study found that ritlecitinib was well tolerated in children aged 6 to under 12 years with severe alopecia areata, with ongoing trials examining its efficacy and safety over a 24-week period and in long-term use up to 36 months.

Some patients on anti-TNF drugs experience a type of hair loss called TAIAPA.

In this study, researchers identified a cluster of hair-specific keratin-associated protein genes within the 21q22.3 region, revealing a novel transcription mechanism involving TSPEAR/C21orf29 that may bypass typical transcriptional termination sites.

This case study reports that a patient receiving Bojungikki-tang alongside chemotherapy showed improvement in hair loss despite ongoing treatment, suggesting a potential benefit for chemotherapy-induced alopecia.

In this study using a mouse model, the authors reported that the synthetic antioxidant TS-13 effectively inhibited tumor growth comparably to doxorubicin and reduced chemotherapy side effects, such as weight loss, splenotoxicity, and alopecia, more effectively when combined with the cytostatic treatment.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study found that dihydrotestosterone induces hair loss in male C57BL/6 mice, and this effect can be partially reversed by the androgen receptor antagonist bicalutamide.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

This study reported that tryptanthrin, a compound found in indigo naturalis, effectively suppresses non-melanoma skin cancer in mice by reducing inflammation, inhibiting cell proliferation, and blocking specific signaling pathways associated with tumor growth.

In this study, a taurine-based ionic liquid was developed to effectively penetrate the skin barrier and deliver antioxidants to hair follicles, reducing oxidative stress and promoting hair regrowth in an androgenic alopecia animal model.

This review discusses various types of microneedles and their potential to expand the range of drugs delivered via the skin, but reports no new clinical results.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

The researchers reported that administration of the antioxidant compound TS-13 in mice with chemotherapy-induced alopecia accelerated hair regrowth, although it did not fully prevent chemotherapy-related hair loss, suggesting TS-13 may aid in managing hair loss without negating the cancer treatment's effectiveness.

This study found that a microneedle patch containing tofacitinib-loaded nanoparticles significantly increased hair follicle numbers and promoted hair regeneration with less drug compared to daily topical tofacitinib, suggesting it may be an effective strategy for alopecia treatment by reducing dosing frequency and enhancing drug delivery.

This article discusses the human KRT72 wild-type allele's role in hair formation and reports no new research findings.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

In this study, hibiscus leaf extract hair tonic at 10% concentration showed better hair growth promotion activity compared to minoxidil 2% in a rabbit model, although it caused eye irritation.

In this study, human-hair artificial tendon material showed good biocompatibility and variable degradation rates in rabbits, depending on treatment time, with minimal inflammatory reactions observed.